TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04635605
Drug: Control Test
Normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: Control Group. Placebo capsules 100 mg twice a day for 5 consecutive days, will be added to the current therapy of the patient, if any.
Study: NCT02660008
Drug: ZP4207
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
Study: NCT03856268
Drug: 'Drug-Induced Menopause' Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.
Study: NCT01607203
Drug: Decapeptyl Daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decapeptyl 0.2 mg SC once 1day
Study: NCT01629199
Drug: placebo of rhEGF(recombinant human Epidermal Growth Factor)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568633
Drug: Best standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention consist of:~* Consolidation chemotherapy (3-4 cycles of cytarabine +/- an anthracycline agent, or other consolidation)~* Autologous transplantation~* Non-Myeloablative unrelated-donor transplant, +/- TLI and ATG conditioning~* Umbilical cord blood transplantation~* Haploidentical transplantation
Study: NCT05043324
Drug: AntiCov-220 (1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The daily maintenance, AntiCov-220 (1) dose is to take 3 times a day, 1 tablet each time.
Study: NCT05043324
Drug: AntiCov-220 (2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The daily maintenance, AntiCov-220 (2) dose is to take 3 times a day, 1 tablet each time.
Study: NCT00566202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form= capsule, route= oral use. Administration once daily for 8 weeks.
Study: NCT00305929
Drug: Treatment with Tookad VTP
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00305929
Drug: Treatment with Tookad VTP
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tookad 2 mg/kg
Study: NCT00305929
Drug: Treatment with Tookad VTP
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg
Study: NCT00068770
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
Study: NCT01948856
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals
Study: NCT04458324
Drug: Buspirone placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects take a placebo tablet twice a day for 6 months.
Study: NCT02660138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study: NCT02660138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study: NCT03618589
Drug: Opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the opioid group received the only opioid (5mg of oxycodone three times a day) for 8 weeks.
Study: NCT02564952
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: GWP42003-P was presented as an oral solution containing 100 mg/milliliter (mL) cannabidiol (CBD) in the excipients sesame oil and anhydrous ethanol (79 mg/mL) with added sweetener (0.5 mg/mL sucralose) and strawberry flavoring (0.2 mg/mL). Participants received up to a maximum of 30 mg/kg/day.
Study: NCT00993629
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: adjunctive placebo
Study: NCT04268823
Drug: QBW251
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule 300mg
Study: NCT04268823
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule 300mg
Study: NCT04276727
Drug: MINT study IMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of gel for 6 weeks.
Study: NCT02379650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01527942
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Acetaminophen 1,000 mg IV
Study: NCT01527942
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
Study: NCT00580931
Drug: Nicotinamide
Normalized name: Nicotinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1500 mg twice a day for 6 months
Study: NCT00580931
Drug: Enduramide placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tab twice a day
Study: NCT00043550
Drug: Pill Placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a pill placebo.
Study: NCT03125239
Drug: LY2874455
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
Study: NCT00137540
Drug: anti-arrhythmic drug therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03054168
Drug: Sustanon 250
Normalized name: SUSTAGEN PWDR CHOCOLATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
Study: NCT01917656
Drug: sulphonylurea
Normalized name: metformin and sulfonylureas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
Study: NCT00322972
Drug: Mass treatment with oral azithromycin to an entire community
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
Study: NCT03717272
Drug: AEF0117
Approvals — FDA: no, EMA: no, PMDA: no
Description: AEF0117 capsules
Study: NCT03717272
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corn oil capsule manufactured to mimic AEF0117 capsule
Study: NCT02970682
Drug: SFX-01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilised Sulforaphane
Study: NCT02970682
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02687867
Drug: Vitamin K antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed by treating physicians
Study: NCT00254579
Drug: CP-675,206
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg Q12W dosing regimen
Study: NCT02251431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohort A only
Study: NCT01042379
Drug: Standard Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
Study: NCT01042379
Drug: PLX3397
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm is closed.
Study: NCT00917293
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 pills, po bid.
Study: NCT03317301
Drug: HL151
Normalized name: Hydroxylapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
Study: NCT03317301
Drug: Talion Tab
Normalized name: BENZOCAINE 5 g in 100 mL TOPICAL CREAM [Stallion]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
Study: NCT01042379
Drug: ARX788
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARX788, 1.5 mg/kg Q3W, IV for 12 weeks
Study: NCT02864901
Drug: Chewing Gum Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02630901
Drug: PRX003
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00745459
Drug: NPO-11
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL NPO-11
Study: NCT00739206
Drug: SAR97276A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose based on body weight
Study: NCT03187899
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
Study: NCT06103656
Drug: Drug: Chinese Herbal Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, 26 month course, starting 2 months pre-OIT.
Study: NCT06103656
Drug: Drug: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules that look identical to E-B-FAHF-2 containing corn starch, 26 month course, starting 2 months pre-OIT
Study: NCT02622906
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicule injection per month during 6 months
Study: NCT02116335
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress response and vascular function will be assessed 3 days following twice per day placebo
Study: NCT01836094
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, one time
Study: NCT04434378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo will be given to a randomized group of patients
Study: NCT00718562
Drug: AMN107
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04008797
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin dosing.
Study: NCT00896038
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-active placebo
Study: NCT00946556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo po od for 2 months
Study: NCT00185107
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01876628
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
Study: NCT01876628
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
Study: NCT02439359
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01954927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
Study: NCT00003388
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003388
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003388
Drug: pegylated liposomal doxorubicin hydrochloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02848729
Drug: Oral Acetaminophen
Normalized name: acetaminophen Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen for oral administration (2 tablets, 500 mg/tablet)
Study: NCT02848729
Drug: IV Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen for intravenous (IV) administration (1,000 mg/100 mL)
Study: NCT02848729
Drug: Placebo Tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets matching oral acetaminophen
Study: NCT00361413
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: these patients will receive the same treatment as group A, without alefacept
Study: NCT00018174
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00018174
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00693862
Drug: levodopa, carbidopa, entacapone
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00693862
Drug: levodopa, carbidopa
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00998218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
Study: NCT02612662
Drug: AZD4076
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
Study: NCT02612662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
Study: NCT00242567
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.~After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.~The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes.
Study: NCT01277107
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo capsule
Study: NCT00308100
Drug: Hydroxyethylstarch 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
Study: NCT00308100
Drug: 5% Albumin
Normalized name: Flexbumin 5% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% albumin, administered intra- and perioperatively
Study: NCT04311411
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC.
Study: NCT02305329
Drug: BIA 9-1067
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01650012
Drug: eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: target 50 mg per day titrated down for hyperkalemia or hypotension
Study: NCT01650012
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01975324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (sugar pill) twice a day for two weeks
Study: NCT00471809
Drug: Budesonide + Salmeterol + Azithromycin
Normalized name: salmeterol and budesonide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04322318
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04322318
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT02437318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of placebo tablets for oral use administered once daily
Study: NCT00528970
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to MOA-728 will be administered per the schedule specified in the arm.
Study: NCT00412373
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: for 6 weeks
Study: NCT03669640
Drug: RO6889450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a once-daily, oral dose of RO6889450 for 12 weeks.
Study: NCT03669640
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a once-daily, oral dose of placebo matched to RO6889450 for 12 weeks.
Study: NCT01186744
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
Study: NCT01186744
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral BID
Study: NCT01186744
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
Study: NCT01186744
Drug: CP-690,550
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral BID
Study: NCT01031420
Drug: single arm dose dense MVAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
Study: NCT05441878
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin arm for resuscitation fluid
Study: NCT04314544
Drug: matching placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: one 1 mL injection of placebo
Study: NCT02454361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00547001
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1mg during stabilization \& then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
Study: NCT03169738
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
Study: NCT03169738
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
Study: NCT03169738
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Calcium N-\[p-\[\[\[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl\]methyl\]amino\]benzoyl\]-L-glutamate (1:1)
Study: NCT00027833
Drug: FOLFIRI regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00027833
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00027833
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02279407
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to Omega-3 carboxylic acids (olive oil)
Study: NCT02279407
Drug: Omega-3 carboxylic acids
Normalized name: omega-3 carboxylic acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g administered as 4 x 1 g capsules
Study: NCT02279407
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to dapagliflozin 10 mg
Study: NCT01149954
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
Study: NCT00958438
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
Study: NCT03430037
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00297882
Drug: 1. Artemether-Lumefantrine (AL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
Study: NCT02118896
Drug: FK506E
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02106793
Drug: Mitomicin C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
Study: NCT02328053
Drug: Topical anti-fungal therapy
Normalized name: miconazole nitrate Topical Cream [Anti-Fungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical antifungal medications like natamycin eye drops and voriconazole eye drops
Study: NCT02106793
Drug: Identical placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identical placebo solution